MARKET

CYDY

CYDY

Cytodyn Inc
OTCMQB
0.295
-0.001
-0.34%
Closed 15:50 06/09 EDT
OPEN
0.300
PREV CLOSE
0.296
HIGH
0.300
LOW
0.285
VOLUME
789.94K
TURNOVER
231.96K
52 WEEK HIGH
0.397
52 WEEK LOW
0.209
MARKET CAP
404.07M
P/E (TTM)
-9.2188
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CYDY last week (0601-0605)?
Weekly Report · 1d ago
Natera, CytoDyn collaborate to advance ctDNA-guided development
TipRanks · 5d ago
CytoDyn partners with Natera to study ctDNA response in metastatic colorectal cancer trial
PUBT · 5d ago
Natera partners with CytoDyn on ctDNA analysis for metastatic colorectal cancer study
PUBT · 5d ago
Weekly Report: what happened at CYDY last week (0525-0529)?
Weekly Report · 06/01 10:33
Weekly Report: what happened at CYDY last week (0518-0522)?
Weekly Report · 05/25 10:37
Weekly Report: what happened at CYDY last week (0511-0515)?
Weekly Report · 05/18 10:36
CytoDyn CFO Hoffman presents at LD Micro Invitational XVI conference
PUBT · 05/15 12:31
More
About CYDY
CytoDyn Inc. is a clinical-stage oncology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses, such as metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.

Webull offers CytoDyn Inc stock information, including OTCMQB: CYDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYDY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYDY stock methods without spending real money on the virtual paper trading platform.